Immune system plays the most critical function in maintaining the health status of human body.  In response to pathogens, our immune system recruits both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system to protect ourselves from further damage.  Immunotherapy revolutionized the field of cancer therapy in which dysregulated immune responses have an important role.  Specific antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4), as well as antibodies against programmed cell death 1 (PD-1) and its ligand PD-L1, have been used in many kinds of cancers and transformed the landscape of cancer therapy.  Although a groundbreaking success, immunotherapy does not work on all cancer types and patients.  Thus, more effective and individualized therapies are highly desired for an improved response rate in immuno-oncology. 

​On the other hand, overactive immunity, under special circumstances, may attack our own cells and cause autoimmune diseases. In the past decade, tremendous progress has been made in the therapy of autoimmune diseases, such as JAK inhibitors targeting JAK-STAT signaling pathways, PED4 inhibitors targeting pro-inflammatory and anti-inflammatory cytokines synthesis and cell proliferation, S1P1/5 receptor modulator targeting Ras, ERK, and PI3K pathways, etc.  Due to the importance of these pathways in normal function of different organs, systemic interference of these pathways will cause unavoidable adverse effects.  We believe precise targeting of these pathways with our unique technology will maximize the efficacy in diseased tissues whereas minimize the systemic side effects.
​
Metabolic diseases, including obesity, diabetes, and NASH, are major causes of increased mortality in past decades.  Therapies in the field, especially diabetes, have been made available thanks to the progress of the research and development.  SGLT-2 inhibitors, GLP-1 and analogs, DPP4 inhibitors, as well as insulin and artificial islet makes diabetes a well-controlled chronic disease.  Interestingly, SGLT-2 inhibitors not only efficiently lower blood glucose but also improve cardiovascular event of diabetics, although the exact mechanism is still not fully understood.  We focus on a proprietary platform to develop novel therapeutics for body weight and glucose control, while avoid systemic adverse effects of the known targets.   Further disclosure of our technical platform will be updated soon.